Skip to content

Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial

Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02153606
Enrollment
30
Registered
2014-06-03
Start date
2015-01-31
Completion date
Unknown
Last updated
2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Feeding Intolerance in Premature Infants

Keywords

Glycerin Suppositories, Enteral Nutrition, Enterocolitis, Necrotizing, Infant, Premature, Meconium

Brief summary

All premature babies have problems with feeding and nutrition. Some can develop a life-threatening bowel infection necrotizing enterocolitis. This can result in the need for emergency surgery, loss of bowel, lifelong feeding problems, and death. Giving premature babies glycerin suppositories may be one way to stimulate the digestive tract and help prevent these problems. To see if this treatment works, the investigators need to study hundreds of premature babies in a large trial involving multiple hospitals. The purpose of this project is to carry out a small study first and make sure that the larger trial is feasible. The investigators will invite approximately 30 premature babies from the Neonatal Intensive Care Unit at McMaster University Medical Centre to participate in this study over a 6-month period. The investigators will focus on feasibility issues, including cost, safety, and rate of participation. This will allow us to rigorously test our study protocol and lay the groundwork for the larger study involving multiple hospitals.

Interventions

The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.

OTHERSham Suppository

Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.

Sponsors

McMaster Surgical Associates
CollaboratorOTHER
Hamilton Health Sciences Corporation
CollaboratorOTHER
McMaster University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Gestational age 24-32 weeks OR * Birth weight 500-1500 grams

Exclusion criteria

* Congenital gastrointestinal anomalies * Surgery within 48 hours of birth * Culture-proven sepsis\* * Vasopressors within 6 hours of first intervention * Nitric oxide * Duct-dependent congenital heart defect requiring prostaglandins * Suspected coagulopathy (mucosal bleeding from any orifice) * Confirmed coagulopathy (any one of the following): * International Normalized Ratio greater than 1.4 * Partial Thromboplastin Time greater than 39 seconds * Fibrinogen less than 1.00 grams/liter * Thrombocytopenia (platelet count less than 100 x 10\^9/liter)\*\* * Neutropenia (absolute neutrophil count less than 0.5 x 10\^9/liter) * Complete meconium evacuation (2 normal bowel movements) within 48 hours of life * Parent or legal guardian unable to understand English Note: \* C-reactive protein is not an

Design outcomes

Primary

MeasureTime frame
Days to full enteral feeding (150 ml/kg/day)Up to 4 months

Secondary

MeasureTime frameDescription
Compliance with treatment regimenUp to 4 months
Days of parenteral nutritionUp to 4 months
Necrotizing enterocolitisUp to 4 months
Culture-proven line sepsisUp to 4 months
MortalityUp to 4 months
Feeding volume on day 14 of life (ml/kg/day)14 days
Days to complete meconium evacuationUp to 4 monthsNumber of days to complete meconium evacuation (defined as two normal bowel movements free of meconium staining).

Other

MeasureTime frameDescription
Treatment-related adverse eventsUp to 4 monthsRectal perforation, rectal bleeding, and/or anal fissure
Cost6 months
Recruitment rate6 monthsPercentage of eligible infants randomized
Completion rate6 monthsPercentage of randomized infants reaching full enteral feeds

Countries

Canada

Contacts

Primary ContactHenrietta Blinder, BSc
blinderh@mcmaster.ca905-521-2100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026